International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 3 , Pages 825-830 , 1 November 2007

Phase I Trial of Gross Total Resection, Permanent Iodine-125 Brachytherapy, and Hyperfractionated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme

  • Allen M. Chen, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • Susan Chang, M.D.

      Affiliations

    • Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • Jean Pouliot, Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • Penny K. Sneed, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • Michael D. Prados, M.D.

      Affiliations

    • Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • Kathleen R. Lamborn, Ph.D.

      Affiliations

    • Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • Mary K. Malec, B.S.

      Affiliations

    • Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • Michael W. McDermott, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA
    • Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • Mitchell S. Berger, M.D.

      Affiliations

    • Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, CA
    • ,
  • David A. Larson, Ph.D., M.D.

      Affiliations

    • Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA
    • Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, CA
    • Corresponding Author InformationReprint requests to: David A. Larson, Ph.D., M.D., Department of Radiation Oncology, L-08, University of California, San Francisco School of Medicine, 505 Parnassus Ave., San Francisco, CA 94143-0226. Tel: (415) 353-8900; Fax (415) 353-8679

Received 6 December 2006 ,Revised 27 March 2007 ,Accepted 28 March 2007.

References 

  1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  2. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–710
  3. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro-oncol. 2004;6:227–235
  4. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239–244
  5. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16:1405–1409
  6. Garden AS, Maor MH, Yung WK, et al. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol. 1991;20:99–110
  7. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24:55–57
  8. Salazar OM, Rubin P, Feldstein ML, et al. High dose radiation therapy in the treatment of malignant gliomas: Final report. Int J Radiat Oncol Biol Phys. 1979;5:1733–1740
  9. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725–1731
  10. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer. 1991;64:769–774
  11. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51:343–355
  12. Laperriere NJ, Leung PMK, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998;41:1005–1011
  13. Scharfen CO, Sneed PK, Wara WM, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys. 1992;24:583–591
  14. Halligan JB, Stelzer KJ, Rostomily RC, et al. Operation and permanent low activity I-125 brachytherapy for recurrent high grade astrocytomas. Int J Radiat Oncol Biol Phys. 1996;35:541–547
  15. Sneed PK, Prados MD, McDermott MW, et al. Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery. 1995;36:898–904
  16. Prados MD, Gutin PH, Phillips TL, et al. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: The UCSF experience. Int J Radiat Oncol Biol Phys. 1992;24:593–597
  17. Gutin PH, Prados MD, Phillips TL, et al. External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG Study 6G-82-2. Int J Radiat Oncol Biol Phys. 1991;21:601–606
  18. Larson DA, Suplica JM, Chang SM, et al. Permanent iodine125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-oncol. 2004;6:119–126
  19. Haas-Kogan DA, Kogan SS, Yount G, et al. P53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys. 1999;2:399–403
  20. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  21. McDermott MW, Gutin PH, Larson DA, et al. Interstitial brachytherapy. Neurosurg Clin North Am. 1990;1:801–824
  22. Wen PY, Alexander EA, Black PM, et al. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994;73:3029–3036
  23. Fernandez PM, Zamorano L, Yakar D, et al. Permanent iodine-125 implants in the up-front treatment of malignant glioma. Neurosurgery. 1995;36:467–473
  24. Schupak K, Malkin M, Anderson L, et al. The relationship between the technical accuracy of stereotactic interstitial implantation for high grade gliomas and the pattern of tumor recurrence. Int J Radiat Oncol Biol Phys. 1995;32:1167–1176
  25. Shrieve DC, Alexander E, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995;36:275–282
  26. Bernstein M, Laperriere N, Glen J, et al. Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1994;30:1213–1217

 Conflict of interest: none.

PII: S0360-3016(07)00668-2

doi: 10.1016/j.ijrobp.2007.03.061

International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 3 , Pages 825-830 , 1 November 2007

Article Tools

* Image Usage & Resolution